Limited therapies exist for patients with refractory and relapsed (RR) higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50 mg) has activity as frontline therapy in elderly AML but there is limited data in the RR setting. This phase II trial included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50 mg) on days 1-28 of 42-day cycles. The primary endpoint was response rate using the 2006 International Working Group criteria. Overall survival (OS) was estimated by Kaplan-Meier methods. Of 27 patients enrolled, 59% had HR-MDS and 31% AML-TD. No patient had isolated del5q; 41% had poor-risk karyotype. Of 9 patients treated at 15 mg, 56% completed ≥2 cycles with no responses. Of 18 patients treated at 50 mg, 39% completed ≥2 cycles and 11% responded but all experienced grade 3/4 neutropenic fever/infection. The 60-day mortality rate was 30%. Median OS was 114 days with 19% surviving ≥1 year. The study was terminated due to lack of robust clinical activity. In conclusion, lenalidomide at 15 mg is ineffective in RR myeloid malignancies. Continous high dosing schedules are poorly tolerated and minimally active. Further evaluation should be considered in upfront intensive chemotherapy-ineligible patients.
Patients with relapsed/refractory higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia with trilineage dysplasia (AML-TD) experience poor outcomes with a median overall survival (OS) of less than 6 months and have very limited therapeutic options despite many years of research into improved therapeutic agents (Estey, 2000; Jabbour et al, 2010; Prebet et al, 2011; Wang et al, 2011; Zeidan et al, 2012) . Elderly patients with comorbidities who have refractory myeloid malignancies fare poorly due to their inability to tolerate aggressive salvage therapies including allogeneic haematopoietic stem cell transplantation (alloHSCT), the only potentially curative treatment strategy (Zeidan et al, 2013a (Zeidan et al, , 2015a .
Lenalidomide is an oral agent that has clinical activity and US Food and Drug Administration approval across a spectrum of haematological malignancies, including multiple myeloma (MM), lower-risk myelodysplastic syndromes with deletion 5q (del5q LR-MDS), and mantle cell and other subtypes of lymphomas (Abou Zahr et al, 2014) . Lenalidomide is classically described as an immunomodulatory agent, but high impact discoveries continue to shed light on previously unrecognized aspects of the pleiotropic effects of the drug that appear to be disease-, karyotype-and potentially dosedependent in different settings (Zeidan et al, 2015b; Abou Zahr et al, 2016) . In LR-MDS for example, lenalidomide has clear differential clinical activity with transfusion-independence rates of 56-67% and a median response duration of 2Á2 years among patients with del5q compared to 25% response rate and a median duration of 33-41 weeks among those without del5q (List et al, 2006 (List et al, , 2014 Raza et al, 2008; Fenaux et al, 2011; Zeidan et al, 2013b; Santini et al, 2016) . Lenalidomide affects karyotype-dependent pathways by impacting haplosufficient genes in del5q patients such as the casein kinase 1a (CSNK1A1) while it exerts karyotype-independent pathways in non-del5q patients by potentially impacting immune function, microenvironment, erythroid differentiation genes, and angiogenesis (Kronke et al, 2015; Abou Zahr et al, 2016) . Regarding the dosing options, in MM the recommended dose of lenalidomide is 25 mg daily while a lower dose is used in non-del5q LR-MDS (5-10 mg daily for 21-28 days/28 days).
The effects of lenalidomide and optimal dose in HR-MDS and AML are less clear. A phase 2 trial of lenalidomide given at 10 mg in patients with HR-MDS with del5q reported a transfusion-independence rate of 26% with a median duration of 6Á5 months (Ades et al, 2009) . Two phase 2 clinical trials reported clinical benefit using single agent high dose (HD) lenalidomide monotherapy in elderly patients with untreated AML with and without del5q (Fehniger et al, 2011; Sekeres et al, 2011) . The first study treated 33 elderly AML (regardless of karyotype) with HD lenalidomide as frontline treatment and reported an overall complete remission (CR)/ complete remission with incomplete recovery (CRi) rate of 30% with best activity observed in patients with lower white blood cell (WBC) counts and blast percentages (Fehniger et al, 2011) .
Another phase 2 clinical trial evaluated HD lenalidomide monotherapy as frontline treatment in 37 elderly AML patients who declined intensive chemotherapy (Sekeres et al, 2011) . Five patients (14%) achieved partial remission (PR) or CR, of whom 2 had isolated del5q and 3 had complex karyotype with a median relapse-free survival of 5 months for responders and a median OS of 2 months for the entire cohort (Sekeres et al, 2011) . Other studies evaluated concurrent or sequential combinations of different doses of lenalidomide with azacitidine or other agents for patients with HR-MDS and AML (Sekeres et al, 2012; Platzbecker et al, 2013; Zeidan et al, 2013c) . Given that most studies of high dose lenalidomide monotherapy in myeloid malignancies were in the upfront setting, we have sought to formally study its use in patients with AML-TD or HR-MDS who were refractory or relapsed following frontline therapy in this phase 2 investigator-initiated trial.
Methods

Patient eligibility and selection
This phase II single-arm study conducted at Johns Hopkins University enrolled patients with histologically confirmed HR-MDS (defined as International Prognostic Scoring System risk categories of high or Intermediate-2) and patients with AML-TD regardless of karyotype. Patients were required to be 18 years of age or older at time of consent, have an Eastern Cooperative Oncology Group performance status of 0-2, and have adequate liver and renal function (defined as serum creatinine ≤176Á8 lmol/l, total bilirubin ≤34Á2 lmol/l, and liver aminotransferase levels ≤5 upper limit of normal). There were no upper limits on age or on the number of prior relapses. The original study and its subsequent two amendments were approved by the Johns Hopkins Medical Institutional Review Board (IRB). All patients provided informed consent, and the study was conducted in accordance with regulations of the local IRB and the Declaration of Helsinki. The study was registered with the National Cancer Institute at http://clinicaltrials.gov with identifier NCT00867308. Lenalidomide was supplied by Celgene (Summit, NJ, USA).
Treatment plan
Lenalidomide monotherapy was administered daily on days 1-28 of 42-day cycles for the first 2 cycles of therapy. The protocol was originally designed using a lenalidomide dose of 15 mg/day, which was the dose that the first 9 patients on the study received. No modifications were required for toxicity. The protocol was later amended, based upon evolving knowledge in the field, to increase the lenalidomide dose for subsequent patients to 50 mg/day with the goal of monitoring for additional toxicity at the higher doses and increasing response rates. This evolution from the original protocol was made based upon newer data from publications of two phase 2 trials suggesting safety and activity of this dose of lenalidomide for upfront management of AML in elderly patients (Fehniger et al, 2011; Sekeres et al, 2011) . Up to 3 weeks off treatment were allowed for count recovery but dose reductions for haematological toxicity were not allowed. Responses were assessed between days 29 and 42 of cycle 2. Patients who achieved objective responses were allowed to continue maintenance therapy with lenalidomide till progression or unacceptable toxicity. Maintenance therapy with lenalidomide was planned at a dose of 25 mg/day on days 1-28 of a 42-day cycle with dose reductions for haematological toxicity. Patients who achieved stable disease (SD) after the first 2 cycles of therapy were administered 2 additional cycles of treatment, whereupon response was again assessed. Toxicity was monitored throughout. Patients achieving a response were to be continued to maintenance therapy. Patients who progressed and those without evidence of response after 4 cycles were taken off-study.
Toxicity assessment
All adverse events were graded and reported by the treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf). Haematological toxicity was not considered in evaluating toxicity except where bone marrow (BM) aplasia lasted for more than 3 weeks from last dose of lenalidomide with an overall BM cellularity <5% or lower with no evidence of leukaemia. Dose delays or dose reductions of lenalidomide for haematological toxicity were not allowed per protocol except during the maintenance phase. Delays and reductions were permitted for other toxicity. The protocol required that a new course of lenalidomide may begin on the scheduled Day 1 of a new cycle only if: (i) any drug-related rash or neuropathy that may have occurred had resolved to ≤grade 1 severity; (ii) Any other grade 3 non-haematological drug-related adverse events that may have occurred had resolved to ≤grade 2 severity. Patients experiencing grade 3 non-haematological toxicity considered by the investigator to be possibly or likely to be related to lenalidomide had the drug held until toxicity recovered to ≤grade 2, and then restarted at 5 mg/day less than the previous dose schedule. Similar dose reductions were allowed in subsequent cycles until the patient reached a 5 mg dose. Patients who experienced grade 3 or greater toxicity while receiving lenalidomide 5 mg/day were not eligible for further treatment with lenalidomide and were taken off the protocol. Infectious complications of neutropenia were not considered non-haematological toxicity.
Efficacy assessment
Bone marrow aspirates and biopsies were performed at end of cycle of 2, end of cycle of 4 for those who had SD at end of cycle 2, and every 3 months thereafter. For MDS, responses were evaluated following cycle 2 (and following cycle 4) according to the International Working Group (IWG) 2006 criteria (Cheson et al, 2006) . Objective responses included CR, PR and haematological improvement (HI). For AML, responses were evaluated using the IWG 2003 criteria (Cheson et al, 2003) . Objective responses included CR, CR with incomplete blood count recovery (CRi) and PR. CR was defined as 4 weeks of peripheral blood neutrophil count ≥1Á0 9 10 9 /l, platelet count ≥100 9 10 9 /l; haemoglobin concentration or haematocrit had no bearing on remission status. Leukaemic blasts could not be present in the peripheral blood. Cellularity of >20% in BM biopsy with maturation of all cell lines and ≤5% blasts was required. For PR, all criteria for CR were required except that the BM could contain >5% blasts but <25% blasts or blasts decreased by 50% or more over pretreatment. Patients with progressive disease (PD) after cycle 2 or 4 were taken off protocol.
Statistical considerations and sample size
The study design used response [overall response rate (ORR)] and toxicity as co-primary endpoints. The primary endpoints were the proportion of patients who have achieved an objective response (ORR) and the proportion of patients who experienced a toxicity event. Demographics and baseline patient characteristics were summarized descriptively. The non-haematological toxicities were recorded according to NCI-CTCAE 3.0 and summarized by dose levels. Given that the ORR was the primary endpoint of the study, survival was calculated from the first day of lenalidomide to death from any cause or to time of last follow-up using Kaplan-Meier (KM) methods. Because there was potential for substantial toxicity with HD Lenalidomide, the trial formally incorporated toxicity into the primary endpoint using a two-stage design developed by Bryant and Day (1995) . This design simultaneously considers a response as well as toxicity and was developed very similarly to the Simon two-stage design (Simon, 1989) . In this patient population, an ORR of 25% was considered worthy of further exploration. A Bryant and Day design was used to simultaneously evaluate the null and alternative response probabilities of 5% and 25% and distinguish acceptable and unacceptable non-toxicity probabilities of 0Á9 and 0Á75 respectively (i.e. 0Á10 < toxicity < 0Á25).
With type I and II error rates of 10% and an allowed error probability of accepting toxicity of 10%, the optimal solution had 21 patients in the first stage. The statistical rules to determine the outcome of the first stage were implements for response and toxicity. If 1 or fewer patients responded and >16 patients did not experience toxicity, the study would be stopped for inadequate response. If more than 1 patient responded and the number without toxicity was ≤16, the trial would be terminated due to excessive toxicity. If the number of responses was ≤1 and the number of non-toxicities is ≤16, the trial would terminate due to lack of response and excessive toxicity. Based on this, the study would proceed for a potential additional 27 patients for stage two. At the end of the second stage, the treatment would be considered for further study only if the number of responses out of 48 patients was >4 and the number of non-toxicities >39. If the number of responses were ≤4 and the number of nontoxicities were >39, the study would be terminated due to lack of response. If the number of responses were >4 and the number of non-toxicities was ≤39, the trial would be terminated due to excessive toxicity. If the number of responses were ≤4 and the number of non-toxicities were ≤39, the trial would be terminated for lack of response and excessive toxicity.
Results
Demographics and patient characteristics
Twenty seven patients were enrolled between July 2009 and March 2014 (Table I) . Median age was 72 years (range, 47-88 years) and 76% were 65 years in age or older at time of diagnosis. In total, 16 patients (59%) had HR-MDS and 11 had AML-TD (31%). No patient had isolated del5q but 2 patients had del5q as part of a complex karyotype. A poorrisk karyotype was present in 41% of the cohort, while intermediate-risk karyotype was observed in 56% of patients (including normal karyotype in 48% of patients), and none of the patients had good risk cytogenetics (i.e. core binding factor translocations). The median BM blast percentage was 15% for the entire cohort (range, 2-90%), and 40% (range, 25-90%) for the AML-TD patients. The median platelet count was 37 9 10 9 /l (range, 3-293 9 10 9 /l), and 63% of patients had a platelet count of 50 9 10 9 /l or lower. The median WBC count was 2Á4 9 10 9 /l (range, 0Á5-6Á4 9 10 9 /l) while the median haemoglobin was 92 g/l (range, 67-140). All patients had received prior therapy, including hypomethylating agent (HMAs) or intensive chemotherapy with a median number of 1 (range, 1-4) prior regimens. None of the patients had a prior alloHSCT. The first 9 patients (33%) on the study received the 15 mg dose of lenalidomide, while the subsequent 18 patients (67%) received the 50 mg dose of the drug. The median follow-up on study was 67 days (range, 9-245).
Toxicity aassessment
The median number of adminsitered lenalidomide cycles was 1 (range, 0-4). None of the patients proceeded to maintenance therapy. Among the 9 patients who received 15 mg dose, 5 (55Á6%) completed ≥2 cycles. None of those patients had grade 3 or 4 non-haematological toxicity that was considered likely to be related to lenalidomide. There were no dose reductions in any of these first 9 patients due to toxicity or otherwise. Among the 18 patients treated at 50 mg dose, only 7 (38Á9%) completed ≥2 cycles of therapy. No dose reductions were allowed per protocol. The grade 3/4 nonhaematological toxicities (preset by study criteria) included bleeding (n = 5), dehydration (n = 2), renal failure (n = 2), pericarditis (n = 1) and hypotension (n = 1). Of note, the bleeding events occurred in patients with other toxicities. Additionally recorded were grade 3/4 neutropenic fevers and infections that occurred in 15 patients, including 4 pneumonias. It should be noted that neutropenic infections were not considered in the grade 3/4 non-haematological toxicity definition by study design, given the high risk patient population being studied. For final study evaluation, we considered all patients with grade 3/4 non-haematological toxicities (including neutropenic infections) to assess the risks of the drug. In summary, this resulted in 20 total patients with grade 3/4 non-haematological toxicities. Of these, the grade 3/4 toxicities were considered unrelated or possibly unrelated to lenalidomide in 8 patients. Thus, 12 patients treated with 50 mg were counted as toxicities in the Bryant-Day analysis. Haematological toxicities were not formally assessed given the significant cytopenias at presentation. All patients were intensely transfusion dependent for platelets and red cells throughout their duration on therapy. Overall, 30-and 60-day mortality rates were 14Á8% and 29Á6%, respectively.
Efficacy assessment
Among the 9 patients who received 15 mg dose, zero achieved an objective response. Among the 18 patients treated at 50 mg dose, two patients achieved an objective response for an ORR of 11%. Twelve of the 18 patients (67%) at 50 mg were taken off study due to disease progression while two (11%) came off due to patient decision and the others were removed due to toxicity (22%). The two patients who did have a measurable response ultimately had a PR as best response and these were scored as responses in the Bryant-Day analysis. Both had been diagnosed with AML-TD. One responder had normal karyotype and the other had monosomy 7. The duration of responses was 3 and 4 months respectively. None of the HR-MDS patients responded. The median OS for the entire cohort (Fig 1) was 114 days (range, 15-841). Five patients (18Á5%) survived 1 year or longer. Of those 5 patients, one patient received salvage low dose cytarabine; two underwent alloHSCT but one died shortly after HSCT and the other lived 1-year post transplant but with intense transfusion support, whereas the others chose supportive care alone. The study was stopped due to futility.
Combined toxicity/efficacy (Bryant-Day) analysis
The nine patients treated at 15 mg were not included in this analysis; none of these patients was scored as a response or a toxicity. The 18 patients treated at 50 mg/day were included in the combined toxicity/efficacy analysis. As noted above, two patients were scored as responders (11%); 12 as toxicity. The first stage was to accrue 21 patients; three additional patients had been treated as planned with zero additional responses and three additional toxicities, the study would have met criteria for entering the second stage. However, in the judgment of the investigators, the two responses were inadequately robust to justify potential accrual of an additional 30 patients.
Discussion
Patients with AML-TD and HR-MDS share multiple clinical and pathological features, including a high prevalence of poor-risk cytogenetics, and MDS frequently evolves into AML. Patients with those myeloid malignancies who experience primary or secondary failure of frontline treatment (including HMAs or intensive chemotherapy) have dismal outcomes with limited salvage options. The activity of single agent lenalidomide at 10 mg in patients with HR-MDS with del5q with a transfusion-independence rate of 26% (Ades et al, 2009 ) prompted us to evaluate a lenalidomide dose of 15 mg as a monotherapy salvage regimen in the relapsed/refractory setting. The lack of response and no excess toxicity in the first 9 patients enrolled at 15 mg coupled with the publication of two phase 2 trials suggesting meaningful clinical activity and tolerability of the higher dose of lenalidomide (50 mg daily) for upfront management of elderly AML patients (Fehniger et al, 2011; Sekeres et al, 2011) then encouraged us to amend the protocol and evaluate the use of HD lenalidomide at 50 mg as a salvage oral treatment regimen in this setting. While the study did not meet criteria for termination at the first stage according to Bryant and Day stopping rules, the investigators observed sufficient toxicity in this patient population in absence of robust responses to avoid further exposures for patients. The results presented here of this investigator-initiated phase 2 trial indicate this dose appears to have minimal activity and is not well tolerated as a salvage option for elderly patients with refractory myeloid malignancies.
For the study design, we adopted a similar approach to the study by Fehniger et al (2011) who used 50 mg daily of lenalidomide for up to two 28-day cycles without dose reductions for haematological toxicity among patients ≥60 years old with untreated AML to be followed by maintenance lenalidomide at 10 mg daily in absence of PD. Among 33 patients with a median age similar to our study (71 years) and similar prevalence of poor-risk karyotypes (39%), a significantly higher percentage of their patients (57%) were able to complete two cycles of HD lenalidomide therapy, and 30% proceeded to maintenance despite 91% of patients experiencing a ≥grade 3 toxicity attributed to lenalidomide. They also observed a substantially higher overall CR/CRi rate (30%) which increased to 53% in 19 patients who completed 2 cycles of HD lenalidomide (Fehniger et al, 2011) . They noted a significantly higher CR/CRi rate in patients presenting with a lower WBC count and lower peripheral blood and BM blast percentages, features resembling HR-MDS. Importantly, the duration of CR/CRi was 10 months (range, 1 to ≥17 months). As was the case in our study, the most common reason for discontinuation of study was PD (61%), while another 24% discontinued therapy due to adverse events. Interestingly, their 30-day mortality was higher than ours (24% vs. 15%) though the 60-day mortality was similar to our study (27% vs. 30%), with 78% of deaths occurring due to disease progression and 22% due to infectious complications (Fehniger et al, 2011) .
In the other study from the South Western Oncology Group (SWOG), 37 untreated elderly AML patients with del5q who declined intensive chemotherapy were similarly treated with lenalidomide at 50 mg daily for 28 days as induction therapy followed by 10 mg daily in cycles of 21 out of 28 days as maintenance therapy (Sekeres et al, 2011) . The median age was 74 years and 23 patients had complex cytogenetics. In total, 38% completed induction and 14% achieved CR/PR (2 had isolated del5q while 3 had complex karyotypes). Seven patients died during induction and 8 started maintenance therapy. The relapse-free survival was 5 months (range, 0-19) while the median OS for the entire cohort was 2 months.
It appears that when HD lenalidomide is used in the salvage setting, a patient population which is sicker and more tenuous and potentially with less BM reserve, the drug may be less well tolerated than in the upfront setting for older patients with myeloid malignancies leading to higher rates of treatment discontinuation. This factor may contribute to lower response rates than observed in those upfront studies due to less total delivery of active drug to the patient. Additionally, resistance mechanisms that lead to disease relapse or refractoriness could be in play in mediating resistance to HD lenalidomide. An intermittent administration schedule of HD lenalidomide to allow the patient treatment breaks might be a better approach if further exploration of HD lenalidomide therapy in the salvage setting is attempted. In line with our observations, a phase 2 trial of the high dose lenalidomide monotherapy (50 mg in 28-day cycles) in patients with HR-MDS after failure of hypomethylating agent therapy has been recently published (Cherian et al, 2016) . Similar to our experience, one-third of patients did not complete the first cycle of therapy and only 38% completed at least 2 cycles with 58% of patients discontinuing protocol treatment due to adverse effects. The investigators also observed >50% significant infection rate. While a 33% marrow CR rate was reported, there were only 8% HI and no CR or PR observed (Cherian et al, 2016) . A major barrier to the optimal use of lenalidomide in advanced myeloid malignancies is the lack of understanding of the mechanisms of action that underlie the clinical activity of the drug, including the dose effects. Better understanding of those mechanisms of action can guide choice of the dose and perhaps selection of patients with higher chance of achieving clinical benefit from this therapy or suggest opportunities for rational lenalidomide-based combination regimens (Zeidan et al, 2013c . In contrast to high grade myeloid malignancies, there have been major breakthroughs in understanding the mechanisms of action of lenalidomide in del5q LR-MDS and MM. For example, the ability of lenalidomide to modulate the substrate specificity of the CRL4 CRBN E3 ubiquitin ligase complex by binding to the cereblon protein and modifying the polyubiquitination, and subsequent proteasome-mediated degradation, of specific substrates has been shown to be instrumental to the drug effects in MM and del5q LR-MDS (Kronke et al, 2014 (Kronke et al, , 2015 . Modulation of the degradation of the transcription factors IKZF1 and IKZF3 is central to the activity of lenalidomide in MM while, in del5q LR-MDS, modulation of casein kinase 1a appears to affect primary mechanisms of action (Kronke et al, 2014 (Kronke et al, , 2015 . In vitro screening of primary samples for cases intolerant of casein kinase 1a or the IKZF transcription factors may identify subsets of patients in whom this approach may be revisited.
In conclusion, HD lenalidomide at 50 mg in 28-day cycles in relapsed/refractory myeloid malignancies appears to be poorly tolerated and minimally active. Those results, combined with the already high costs of myeloid maligancnies to the health care systems (Zeidan et al, 2016a,b) , suggest that the use of HD lenalidomide for refractory myeloid malignancies should be avoided outside the context of clinical trials. Further exploration of HD lenalidomide should consider further evaluation in untreated AML patients who are considered inelgibile for intensive chemotherapy. Additionally, study designs should incorporate early stopping rules for both toxicity and lack of efficacy.
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